Outside of a not completely unexpected merger, it was a relatively quite start to the week. As has been par for the course, ASCO oncology stocks tended to be weak.
It seemed to be a quite day as I think everyone is recovering from the ASCO abstract dump. 1. I had some good discussion with people about the PGNX abstract.
Well, this is my first daily rundown for subscribers and while many of you have received these as emails, this might be new for others. In general, I like to.